HC Wainwright Reaffirms “Buy” Rating for Inventiva (NASDAQ:IVA)

HC Wainwright reissued their buy rating on shares of Inventiva (NASDAQ:IVA) in a report published on Friday,Benzinga reports. They currently have a $13.00 target price on the stock.

Separately, TD Cowen initiated coverage on shares of Inventiva in a research report on Friday, February 21st. They set a “buy” rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $12.60.

Inventiva Stock Down 3.6 %

NASDAQ IVA opened at $2.93 on Friday. Inventiva has a 1-year low of $1.53 and a 1-year high of $3.98. The business’s 50-day simple moving average is $2.70 and its 200-day simple moving average is $2.48.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.